)
Sandoz (SDZ) investor relations material
Sandoz Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Biosimilar strategy and market opportunity
Biosimilar launches targeted to rise from 13 in the past 20 years to 40–50 over the next 15 years; biologic products representing nearly $400B of LOEs are expected over the next 10+ years.
Global biosimilar share is ~20%, with an aspiration to exceed 30%–35% over the next 10 years; competitive intensity per asset is trending down.
A Bio100 strategy could generate $1T in North American healthcare savings over 10 years; ~$600B of products are expected to lose patent protection globally over the next decade.
Management described the coming decade as a major opportunity and plans to focus on biosimilars and generics rather than value-added medicines or digital therapeutics.
Launch pipeline and growth drivers
2027 launches include insulins and other products in Europe, four biosimilars in Japan, and U.S. aflibercept in H2; aflibercept is expected to contribute strongly into 2028.
Biosimilar business grew 17% in the prior quarter; additional launches are expected through 2028 and 2029, including U.S. etanercept in 2029 and pembrolizumab in the following years.
Aflibercept own-label launch is expected to create value from H2 2027, with carryover into 2028 and committed volumes; own-label launches have also been made for adalimumab and ustekinumab.
In-house development candidates are planned to increase from two to seven; most new in-house assets are expected to launch from the mid-2030s, balancing internal development with partner opportunities.
Manufacturing and vertical integration
The Slovenia site has 120,000-liter large fed-batch capacity, is through regulatory phases, and is moving toward operation; the facility and land allow for expansion.
Supply from the existing Novartis relationship may continue alongside technology transfers; the plan is to draw increasing volume from the internal network from 2029.
At least 60% of volume is targeted to come from the owned, vertically integrated supply chain by 2035; small fed-batch, large fed-batch and continuous manufacturing support different production scales.
Internal capacity can improve cost of goods and unlock profitable growth in supply-constrained products such as erythropoietin; partner products are generally less profitable than fully integrated products but more profitable than classic small molecules.
- Biosimilar growth lifted Q3 sales as FY26 margin guidance rose and sales guidance narrowed.SDZ
Q3 2026 TU - Bio 100 targets over 100 biosimilars by 2040, doubling net sales and margin above 30% by 2035.SDZ
CMD 2026 - Biosimilars drove 5% sales growth and margin expansion, confirming a strong full-year outlook.SDZ
Q2 2026 - Biosimilars drove Q1 2026 growth, offsetting generics decline; guidance reaffirmed.SDZ
Q1 2026 TU - Biosimilars drove 5% sales growth and a margin upgrade, now at 31% of Q3 net sales.SDZ
Q3 2025 TU - Strong pipeline, biosimilar launches, and operational gains drive margin and global growth.SDZ
Sandoz Strategic Review 2024 - Q3 sales up 12% and biosimilars up 32%, prompting raised full-year guidance.SDZ
Q3 2024 - Strong 2023 growth, pipeline expansion, and margin targets drive future biosimilars leadership.SDZ
43rd Annual J.P. Morgan Healthcare Conference 2025 - Biosimilars fueled record sales and margin growth in 2024, supporting a strong outlook for 2025.SDZ
Q4 2024
)
)
)
)
)
)
)
)